Yousif Capital Management LLC Sells 10,541 Shares of Johnson & Johnson $JNJ

Yousif Capital Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 320,149 shares of the company’s stock after selling 10,541 shares during the quarter. Johnson & Johnson comprises 0.6% of Yousif Capital Management LLC’s portfolio, making the stock its 15th biggest position. Yousif Capital Management LLC’s holdings in Johnson & Johnson were worth $59,362,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson in the second quarter worth $27,000. Semmax Financial Advisors Inc. increased its position in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth $35,000. 1248 Management LLC bought a new position in Johnson & Johnson during the first quarter worth about $48,000. Finally, Vermillion & White Wealth Management Group LLC grew its stake in Johnson & Johnson by 66.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after acquiring an additional 150 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.1%

JNJ stock opened at $208.01 on Thursday. The company has a market cap of $501.14 billion, a price-to-earnings ratio of 20.08, a P/E/G ratio of 2.23 and a beta of 0.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $215.18. The business has a 50 day moving average price of $199.06 and a two-hundred day moving average price of $180.31. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Analysts Set New Price Targets

A number of research firms have recently commented on JNJ. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Morgan Stanley raised their target price on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Barclays raised their price objective on shares of Johnson & Johnson from $176.00 to $197.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.